378 related articles for article (PubMed ID: 12419747)
1. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
2. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
[TBL] [Abstract][Full Text] [Related]
3. A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W
J Obstet Gynaecol Res; 2003 Jun; 29(3):123-31. PubMed ID: 12841693
[TBL] [Abstract][Full Text] [Related]
4. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA; Holmberg LA; Veljovich D; Kurland BF;
Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
[TBL] [Abstract][Full Text] [Related]
6. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
7. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Greggi S; Salerno MG; D'Agostino G; Ferrandina G; Lorusso D; Manzione L; Mancuso S; Scambia G
Oncology; 2001; 60(1):19-23. PubMed ID: 11150903
[TBL] [Abstract][Full Text] [Related]
8. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J; Stengel D; Oskay-Oezcelik G; Zeimet AG; Sommer H; Klare P; Stauch M; Paulenz A; Camara O; Keil E; Lichtenegger W
J Clin Oncol; 2008 Jul; 26(19):3176-82. PubMed ID: 18591555
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
10. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
Joly F; Petit T; Pautier P; Guardiola E; Mayer F; Chevalier-Place A; Delva R; Sevin E; Henry-Amar M; Bourgeois H
Gynecol Oncol; 2009 Dec; 115(3):382-8. PubMed ID: 19773043
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
Chen MD; Fleming GF; Mitchell S; Horowitz I
Gynecol Oncol; 2006 Jan; 100(1):111-5. PubMed ID: 16150481
[TBL] [Abstract][Full Text] [Related]
12. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
Syrios J; Kouroussis C; Kotsakis A; Kentepozidis N; Kontopodis E; Kalbakis K; Vardakis N; Hatzidaki D; Polyzos A; Georgoulias V;
Minerva Ginecol; 2019 Jun; 71(3):182-190. PubMed ID: 30727721
[TBL] [Abstract][Full Text] [Related]
13. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Murgia V; Sorio R; Griso C; Caffo O; Arcuri C; Ferro A; Caldara A; Scalone S; Arisi E; Galligioni E
Int J Gynecol Cancer; 2010 Aug; 20(6):953-7. PubMed ID: 20683401
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
González-Martín A; Pautier P; Mahner S; Rau J; Colombo N; Ottevanger P; Del Campo JM; Selle F; du Bois A; Gadducci A; García Y; Berton-Rigaud D; Marmé F; Ortega E; Martin N; Bastiere-Truchot L; Kiermaier A; Kurzeder C
Int J Gynecol Cancer; 2016 Jun; 26(5):898-905. PubMed ID: 27206218
[TBL] [Abstract][Full Text] [Related]
17. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Ramasubbaiah R; Perkins SM; Schilder J; Whalen C; Johnson CS; Callahan M; Jones T; Sutton G; Matei D
Gynecol Oncol; 2011 Dec; 123(3):499-504. PubMed ID: 21955480
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
